COVID-19 treatment breakthrough using fibroblast cell therapy in mice

Researchers from FibroGenesis (TX, USA) have shown that PneumoBlast™, a fibroblast-based cell therapy, has significant efficacy when used in treating mice with lung inflammation that resembles COVID-19. Furthermore, the team observed a reduction from infiltration of inflammatory cells and suppression of chemical mediators, such as interleukin-6 (IL-6), which are associated with poor survival in COVID-19 patients. The team stimulated the immune systems of mice to enter hyper-activation mode, which causes symptoms similar to COVID-19. Once COVID-19 stimulation occurred, the mice were administered  PneumoBlast, which caused a significant reduction in lung fluid accumulation. The research group ran another set of experiments...